Naloxone and naltrexone are both opioid antagonists, meaning they block the same receptors in the brain, but they serve fundamentally different purposes. Naloxone is the emergency drug: fast-acting, short-lived, and designed to reverse an overdose in minutes. Naltrexone is the maintenance drug: slow and steady, taken daily or injected monthly to keep cravings and relapse at bay over weeks and months. The confusion between them is understandable because their names differ by just a few letters and their chemistry is remarkably similar, but mixing them up in practice could be dangerous.
How They Work at the Receptor Level
Both drugs attach to the mu-opioid receptor, the same docking site that heroin, fentanyl, morphine, and your body’s own endorphins use. Once either drug parks itself on that receptor, opioids cannot activate it. The mechanism is competitive antagonism: picture two molecules racing for the same parking spot. If naloxone or naltrexone gets there first, or muscled in with enough force, the opioid is locked out and its effects are blocked or reversed.
What separates the two drugs is how long they stay attached. Naloxone binds quickly but loosely, so its effects wear off in roughly 30 to 90 minutes depending on the route of administration. Naltrexone grips the receptor far more tightly and for much longer, producing a blockade that lasts about 24 hours with a single oral dose or up to a month with an extended-release injection. The chemical reason comes down to small structural differences in their molecules. Research on their morphinan scaffolds shows that swapping just one small chemical group, a methyl-cyclopropyl versus an allyl group, along with a change at another position on the molecule, dramatically alters how each drug behaves in the body.1ACS Medicinal Chemistry Letters. How Subtle Molecular Differences in the Morphinan Opioid Antagonists Affect Their Physicochemical and In Vitro ADME Properties
Naloxone in an Overdose Emergency
Naloxone exists for one primary scenario: someone has stopped breathing or is breathing dangerously slowly because of an opioid. It is currently the only approved treatment for reversing opioid-induced respiratory depression.2Anesthesiology. Opioid Overdose: Limitations in Naloxone Reversal of Respiratory Depression and Prevention of Cardiac Arrest The drug can be given as a nasal spray (the form most bystanders carry), an intramuscular injection, or an intravenous push in a hospital. Within a few minutes, a person who was barely breathing can be awake and talking.
Dosing matters more than many people realize. Clinical evidence shows that small doses, in the range of 0.04 to 0.12 mg intravenously, can be enough to restore breathing without catapulting the patient into full-blown withdrawal.3Annals of Emergency Medicine. Association of Higher Doses of Naloxone With Pulmonary Complications Following Opioid Overdose In cancer patients who have been on opioids long-term, experts recommend titrating slowly, giving 20 to 100 micrograms intravenously every two minutes, because a large bolus can trigger refractory pain and severe withdrawal.4PubMed Central. Importance of the correct diagnosis of opioid-induced respiratory depression in adult cancer patients and titration of naloxone The goal is to get the person breathing adequately, not necessarily fully alert and opioid-free.
Because naloxone wears off so quickly, there is a real risk of “renarcotization,” where the opioid outlasts the naloxone and breathing slows down again. Anyone who receives naloxone should be monitored for at least a couple of hours afterward, especially if the overdose involved a long-acting opioid.
The Fentanyl Complication
The rise of illicitly manufactured fentanyl has put naloxone under stress. Fentanyl is far more potent than heroin, achieves very high concentrations in the body during an overdose, and saturates opioid receptors quickly. Because naloxone works by competition, it has to muscle past a large number of occupied receptors in a very short window. Multiple sequential doses are sometimes needed, and some researchers have argued that higher individual doses should be standard.5PubMed Central. Higher doses of naloxone are needed in the synthetic opiod era One review noted that naloxone, while generally effective against conventional opioids, may not be versatile enough to handle every fentanyl-related overdose, particularly when fentanyl analogues or drug combinations are involved.6PubMed. Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limit
That said, claims that fentanyl has made naloxone obsolete are overblown. A 2024 analysis concluded that the vast majority of fentanyl overdoses can be successfully reversed with two standard intramuscular or intranasal doses, with carfentanil being the major exception, sometimes requiring three or more.7PubMed Central. High-dose naloxone formulations are not as essential as we thought The practical takeaway is to carry enough naloxone to give a second dose and to call emergency services regardless. Long-acting opioids and those with high receptor affinity are particularly resistant to reversal, so the person may need professional monitoring even after they appear to recover.8Anesthesiology. Opioid Overdose: Limitations in Naloxone Reversal of Respiratory Depression and Prevention of Cardiac Arrest
Naltrexone for Opioid Use Disorder
Naltrexone occupies an entirely different clinical niche. Rather than rescuing someone from an acute crisis, it helps people who have already stopped using opioids stay that way. The extended-release injectable form, given once a month, has been the most studied. In a large trial of criminal-justice-involved adults, those receiving the monthly injection had a relapse rate of about 43% over 24 weeks compared to 64% in the usual-treatment group, and their median time to relapse roughly doubled.9PubMed Central. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders A phase III trial also demonstrated significantly higher weeks of confirmed opioid abstinence with the injection compared to placebo.10PubMed. Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients
There is an important catch. Naltrexone can only be started after a person has fully detoxified from opioids, usually requiring at least seven to ten days of abstinence. If naltrexone is introduced while opioids are still in the system, it will rip them off the receptors all at once, triggering precipitated withdrawal, an intensely unpleasant experience that can be medically dangerous and often drives patients away from treatment entirely. Clinical recommendations suggest that bridging from opioids to naltrexone works best with an initial low dose of buprenorphine combined with supportive medications, followed by progressively increasing oral naltrexone doses over three to five days until reaching the target dose.11PubMed Central. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice This detox requirement is one of the biggest practical barriers to using naltrexone, because many patients relapse during the waiting period before they can even start the drug.
Naltrexone for Alcohol Use Disorder
While naloxone has no real role in alcohol treatment, naltrexone is FDA-approved for alcohol use disorder and has been used for this purpose since the 1990s. The theory is that alcohol triggers a release of endorphins, your body’s natural opioids, which contribute to the pleasurable “buzz.” By blocking the receptors those endorphins act on, naltrexone dampens that reward, making drinking feel less satisfying. Studies in alcohol-dependent individuals confirm that naltrexone reduces both the desire to drink and the amount of alcohol consumed.12PubMed. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis Additional research shows that providing naltrexone to people seeking treatment for alcohol dependence accelerates the reduction of craving, consistent with how many addiction treatment programs work.13Alcohol and Alcoholism. Reductions in Alcohol Craving Following Naltrexone Treatment for Heavy Drinking
Unlike its use in opioid treatment, naltrexone for alcohol does not require a detox period. Patients can start taking it while they are still drinking, and the medication gradually makes drinking less rewarding, which for many people leads to a natural reduction in consumption. Some clinicians prescribe it using the “Sinclair method,” where patients take naltrexone specifically an hour before they plan to drink, though this approach is more common in Europe than in the United States and is not the standard FDA labeling.
The Adherence Problem
Naltrexone’s biggest weakness is the same one facing nearly every medication for chronic conditions: people stop taking it. Oral naltrexone, a daily pill, has notoriously poor adherence. A recent randomized trial of hospitalized patients with alcohol use disorder found that only about 27% of those assigned to oral naltrexone had high adherence, compared to roughly 41% with the monthly injection.14JAMA Internal Medicine. Oral vs Extended-Release Injectable Naltrexone for Hospitalized Patients With Alcohol Use Disorder: A Randomized Clinical Trial A meta-analysis comparing the two formulations across multiple studies confirmed that treatment persistence was significantly higher with extended-release injections at both three months and six months.15Drug and Alcohol Dependence. Extended-release naltrexone versus oral naltrexone for substance use disorders: A systematic review and meta-analysis
This is why the injectable form has become preferred in many treatment settings despite its higher cost. When you only have to show up once a month for a shot instead of remembering a pill every day, it takes willpower out of the equation. That said, the injection is not a silver bullet. Even with the monthly shot, a substantial portion of patients stop treatment within the first few months.
Naloxone Inside Combination Products
One reason naloxone and naltrexone get confused is that naloxone shows up in products that sound like they should contain naltrexone, and vice versa. The most common example is buprenorphine/naloxone, sold as Suboxone, a combination used for opioid maintenance therapy. Buprenorphine is a partial opioid agonist that controls cravings and withdrawal. Naloxone is added in a 4:1 ratio as an abuse deterrent: when taken sublingually as directed, the naloxone is barely absorbed and has no meaningful effect, but if someone crushes the tablet and injects it, the naloxone becomes active and triggers withdrawal.16PubMed. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence
Naltrexone also appears in a combination product, paired with bupropion for weight management. The rationale is that naltrexone and bupropion together affect brain circuits involved in food craving and reward.17PubMed. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss This product has nothing to do with opioid treatment, which can surprise people who associate naltrexone exclusively with addiction medicine.
Take-Home Naloxone Programs
Public health efforts around naloxone have expanded enormously. Take-home naloxone programs, which distribute the drug to people at risk of witnessing an overdose, have shown a strong track record. A systematic review found a greater than 96% overdose survival rate among cases where take-home naloxone was administered.18PubMed Central. Are take‐home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria In one opioid treatment program, about 18% of participants who received take-home naloxone went on to perform overdose reversals in the community, mostly on friends, family members, or acquaintances.19JAMA Network Open. Association of Take-Home Naloxone and Opioid Overdose Reversals Performed by Patients in an Opioid Treatment Program A UK modeling study estimated that distributing naloxone to a population of 200,000 heroin users could prevent around 2,500 premature deaths at a cost well below standard thresholds for health interventions.20PubMed. Cost-Effectiveness of Take-Home Naloxone for the Prevention of Overdose Fatalities among Heroin Users in the United Kingdom
In 2023, the U.S. Food and Drug Administration approved an over-the-counter naloxone nasal spray, making it possible to buy the drug without a prescription at pharmacies nationwide. This was a landmark shift in accessibility. Naltrexone, by contrast, always requires a prescription, a medical assessment, and in the case of opioid use disorder, a confirmed period of detox before initiation.
Cost and Comparative Effectiveness
From a health-economics perspective, the two drugs sit in very different cost buckets. Naloxone nasal spray is relatively inexpensive per dose, and community distribution programs have proven cost-effective. Naltrexone, particularly the extended-release injection, is substantially pricier. A cost analysis found that mean 24-week treatment costs for the naltrexone injection exceeded those for buprenorphine-naloxone by over $5,000 per patient, driven by both the cost of the drug itself and the detoxification required beforehand.21PubMed Central. Cost-Effectiveness of Buprenorphine–Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse
A broader modeling study that included criminal justice costs found that all forms of medication-assisted treatment, including naltrexone, produced substantial lifetime savings compared to no treatment, but naltrexone was dominated by other treatment alternatives when criminal justice costs were excluded. The same study noted that naloxone distribution alone, while highly effective at keeping people alive, does not by itself reduce downstream costs unless paired with ongoing addiction treatment.22JAMA Psychiatry. Cost-effectiveness of Treatments for Opioid Use Disorder That finding underscores why the two drugs work best as complements rather than competitors: naloxone saves a life in the moment, and naltrexone (or another maintenance medication) supports recovery over time.
Safety and Liver Concerns
Naloxone’s safety profile is straightforward. The drug itself is essentially nontoxic; the main risk comes from the withdrawal it precipitates in opioid-dependent individuals, not from naloxone harming the body directly. Its brevity of action limits side effects.
Naltrexone has historically carried a black-box warning about liver toxicity, which made many clinicians hesitant to prescribe it, especially to patients with liver disease, a common comorbidity in people with alcohol use disorder. Recent data has calmed those concerns considerably. A study of over 3,200 patients with cirrhosis who were started on naltrexone found that only about 2% had any liver enzyme elevations during the high-risk period, and none were classified as even possible drug-induced liver injury.23ScienceDirect. Safety of naltrexone in patients with cirrhosis The original warning came from studies using much higher doses than are currently prescribed, and the clinical community has increasingly recognized that the risk was overstated for standard dosing.
Low-Dose Naltrexone and Off-Label Uses
Naltrexone at very low doses, typically 1 to 5 mg rather than the standard 50 mg, has developed a fervent following for conditions that have nothing to do with addiction. Dubbed “low-dose naltrexone” or LDN, the idea is that at these tiny doses, the drug briefly and partially blocks opioid receptors, which triggers the body to upregulate its own endorphin production and, more importantly, modulates neuroinflammation by acting on glial cells in the central nervous system.24PubMed. Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review A systematic review characterized LDN as a novel anti-inflammatory and immunomodulator that may provide an alternative approach for managing chronic pain disorders.25PubMed. Use of low-dose naltrexone in the management of chronic pain conditions: A systematic review
LDN has been tried for fibromyalgia, Crohn’s disease, multiple sclerosis, and various chronic pain syndromes. The evidence base is still thin, mostly consisting of small trials and case series rather than the large randomized trials that would settle the question. It is not FDA-approved for any of these conditions, and insurance rarely covers it, so patients typically get it through compounding pharmacies. The enthusiasm around LDN runs well ahead of the published data, but the biological rationale is plausible enough that larger studies are underway.
At standard doses, naltrexone has also been studied for behavioral addictions, an area where there is no FDA approval but growing interest. A meta-analysis of randomized controlled trials found that naltrexone showed a beneficial effect across broadly defined behavioral addictions, including pathological gambling, kleptomania, and compulsive hair-pulling.26European Addiction Research. Naltrexone in the Treatment of Broadly Defined Behavioral Addictions: A Review and Meta-Analysis of Randomized Controlled Trials A study in adolescents with eating disorders found that just over half showed a positive response to naltrexone, with reduced binge-eating and purging behaviors.27PubMed Central. Naltrexone Reduces Binge Eating and Purging in Adolescents in an Eating Disorder Program The common thread in all these uses is the opioid reward system: if a behavior is being reinforced by endorphin-driven reward, blocking that reward may weaken the compulsion.
Naltrexone in Pregnancy
Pregnancy creates unique dilemmas for opioid treatment. Buprenorphine and methadone are the standard of care for pregnant women with opioid use disorder because they stabilize the patient without requiring full detox, which carries its own risks during pregnancy. Naltrexone is less commonly used because it demands that detox happen first. Still, preliminary research is cautiously encouraging. A study of pregnant individuals who began naltrexone therapy found no cases of spontaneous abortion or stillbirth, no concerning changes in fetal heart tracings when the drug was initiated at or after 24 weeks, and no difference in birth anomalies compared to those not on naltrexone.28PubMed. Use of naltrexone in treating opioid use disorder in pregnancy A small case series also reported no fetal anomalies, no neonatal opioid withdrawal syndrome, and maintained sobriety in most participants through delivery and beyond.29PubMed Central. Case Series of Individuals Treated With Naltrexone During Pregnancy for Opioid and/or Alcohol Use Disorder These are small studies, not definitive evidence, but they suggest naltrexone may be a reasonable option for pregnant patients who are already opioid-free and want to remain so.
When Each Drug Makes Sense
The simplest way to keep the two drugs straight is by their timelines. Naloxone is a minutes-long intervention for a life-threatening emergency. You do not take it daily or use it to manage a chronic condition. Naltrexone is a months-to-years commitment to reducing the pull of opioids or alcohol. You would never hand someone a naltrexone pill during an overdose, and you would never put someone on a naloxone maintenance regimen to prevent relapse.
There is also a sequential logic to how the two drugs often appear in the same patient’s story. Someone overdoses on heroin, a bystander administers naloxone, and the person survives. Later, after medically supervised detox, they start naltrexone to reduce the chance of another overdose. One drug gets them through the crisis, the other supports recovery. They work best not as alternatives but as different chapters in the same treatment arc.